MedPage TodayClinical Challenge: Hematologic Malignancy and COVID-19

The inaugural report of the ASH Research Collaborative (RC) COVID-19 Registry for Hematology, published in Blood Advances, is based on an analysis of the first 250 patients with both hematologic malignancy and COVID-19 registered from 74 countries. The analysis showed that the mortality risk (28% overall and increased to 42% among hospitalized patients with COVID-19) was heterogenous and unpredictable, further challenging doctors when allocating resources and determining which patients receive intensive care.